228 related articles for article (PubMed ID: 25125216)
1. Uveitis in patients with late-stage cutaneous melanoma treated with vemurafenib.
Guedj M; Quéant A; Funck-Brentano E; Kramkimel N; Lellouch J; Monnet D; Longvert C; Gantzer A; Brézin AP
JAMA Ophthalmol; 2014 Dec; 132(12):1421-5. PubMed ID: 25125216
[TBL] [Abstract][Full Text] [Related]
2. Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib.
Choe CH; McArthur GA; Caro I; Kempen JH; Amaravadi RK
Am J Ophthalmol; 2014 Oct; 158(4):831-837.e2. PubMed ID: 25036880
[TBL] [Abstract][Full Text] [Related]
3. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
Sinha R; Larkin J; Gore M; Fearfield L
Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
[TBL] [Abstract][Full Text] [Related]
4. Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma.
Wolf SE; Meenken C; Moll AC; Haanen JB; van der Heijden MS
BMC Cancer; 2013 Dec; 13():561. PubMed ID: 24289205
[TBL] [Abstract][Full Text] [Related]
5. Uveitic macular oedema after treatment with vemurafenib.
Fonollosa A; Mesquida M; Adan A
Acta Ophthalmol; 2015 Dec; 93(8):e686-7. PubMed ID: 25683228
[No Abstract] [Full Text] [Related]
6. Sarcoidosis in Patients Treated with Vemurafenib for Metastatic Melanoma: A Paradoxical Autoimmune Activation.
Lheure C; Kramkimel N; Franck N; Laurent-Roussel S; Carlotti A; Queant A; Goldwasser F; Avril MF; Dupin N
Dermatology; 2015; 231(4):378-84. PubMed ID: 26452227
[TBL] [Abstract][Full Text] [Related]
7. [Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma].
Fauviaux E; Promelle V; Boucenna V; Jany B; Errera MH; Delbarre M; Boucenna W
J Fr Ophtalmol; 2022 Jun; 45(6):612-618. PubMed ID: 35501194
[TBL] [Abstract][Full Text] [Related]
8. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.
Larkin J; Del Vecchio M; Ascierto PA; Krajsova I; Schachter J; Neyns B; Espinosa E; Garbe C; Sileni VC; Gogas H; Miller WH; Mandalà M; Hospers GA; Arance A; Queirolo P; Hauschild A; Brown MP; Mitchell L; Veronese L; Blank CU
Lancet Oncol; 2014 Apr; 15(4):436-44. PubMed ID: 24582505
[TBL] [Abstract][Full Text] [Related]
9. Vemurafenib: in unresectable or metastatic melanoma.
Keating GM
BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
[TBL] [Abstract][Full Text] [Related]
10. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
11. Intraocular Inflammation Associated with New Therapies for Cutaneous Melanoma - Case Series and Review.
Fierz FC; Meier F; Chaloupka K; Böni C
Klin Monbl Augenheilkd; 2016 Apr; 233(4):540-4. PubMed ID: 27116532
[TBL] [Abstract][Full Text] [Related]
12. Vemurafenib-induced radiation recall dermatitis: case report and review of the literature.
Conen K; Mosna-Firlejczyk K; Rochlitz C; Wicki A; Itin P; Arnold AW; Gross M; Zimmermann F; Zippelius A
Dermatology; 2015; 230(1):1-4. PubMed ID: 25472806
[TBL] [Abstract][Full Text] [Related]
13. Vemurafenib and radiosensitization.
Boussemart L; Boivin C; Claveau J; Tao YG; Tomasic G; Routier E; Mateus C; Deutsch E; Robert C
JAMA Dermatol; 2013 Jul; 149(7):855-7. PubMed ID: 23699661
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities.
Sinha R; Edmonds K; Newton-Bishop JA; Gore ME; Larkin J; Fearfield L
Br J Dermatol; 2012 Nov; 167(5):987-94. PubMed ID: 22913467
[TBL] [Abstract][Full Text] [Related]
15. Induction vemurafenib followed by consolidative radiation therapy for surgically incurable melanoma.
Seeley AR; De Los Santos JF; Conry RM
Melanoma Res; 2015 Jun; 25(3):246-51. PubMed ID: 25746037
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous manifestations of vemurafenib therapy for metastatic melanoma.
Owen JL; Lopez IE; Desai SR
J Drugs Dermatol; 2015 May; 14(5):509-10. PubMed ID: 25942671
[TBL] [Abstract][Full Text] [Related]
17. A Rare Cause of Uveitis: Vemurafenib.
Sızmaz S; Görkemli N; Esen E; Demircan N
Turk J Ophthalmol; 2018 Dec; 48(6):323-325. PubMed ID: 30605942
[TBL] [Abstract][Full Text] [Related]
18. Vemurafenib. Value unclear in metastatic melanoma.
Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
[TBL] [Abstract][Full Text] [Related]
19. Vemurafenib in the French temporary authorization for use metastatic melanoma cohort: a single-centre trial.
Fennira F; Pagès C; Schneider P; Sidina I; Viguier M; Basset-Seguin N; Madjlessi-Ezra N; Madelaine I; Bagot M; Battistella M; Porcher R; Mourah S; Lebbé C
Melanoma Res; 2014 Feb; 24(1):75-82. PubMed ID: 24241686
[TBL] [Abstract][Full Text] [Related]
20. Early-Onset Vemurafenib-Induced DRESS Syndrome.
Munch M; Peuvrel L; Brocard A; Saint Jean M; Khammari A; Dreno B; Quereux G
Dermatology; 2016; 232(1):126-8. PubMed ID: 26418832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]